Vanguard Group’s Oncternal Therapeutics ONCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-139,884
Closed -$185K – 4385
2024
Q3
$185K Sell
139,884
-3,159
-2% -$15.3K ﹤0.01% 4150
2024
Q2
$1.09M Hold
143,043
– – ﹤0.01% 3764
2024
Q1
$1.29M Sell
143,043
-2
-0% -$18 ﹤0.01% 3729
2023
Q4
$1.53M Hold
143,045
– – ﹤0.01% 3693
2023
Q3
$858K Hold
143,045
– – ﹤0.01% 3890
2023
Q2
$987K Sell
143,045
-162
-0.1% -$1.07K ﹤0.01% 3900
2023
Q1
$2.25M Hold
143,207
– – ﹤0.01% 3630
2022
Q4
$2.86M Buy
143,207
+46
+0% +$916 ﹤0.01% 3532
2022
Q3
$2.55M Buy
143,161
+36,410
+34% +$781K ﹤0.01% 3647
2022
Q2
$2.37M Sell
106,751
-9,525
-8% -$212K ﹤0.01% 3736
2022
Q1
$3.23M Buy
116,276
+9,610
+9% +$350K ﹤0.01% 3739
2021
Q4
$4.84M Buy
106,666
+635
+0.6% +$42.7K ﹤0.01% 3627
2021
Q3
$8.84M Buy
106,031
+651
+0.6% +$53.8K ﹤0.01% 3315
2021
Q2
$10M Buy
105,380
+17,279
+20% +$2.05M ﹤0.01% 3198
2021
Q1
$14.7M Buy
88,101
+4,026
+5% +$532K ﹤0.01% 2944
2020
Q4
$8.24M Buy
84,075
+70,160
+504% +$4.44M ﹤0.01% 3093
2020
Q3
$473K Sell
13,915
-310
-2% -$15.2K ﹤0.01% 3830
2020
Q2
$808K Sell
14,225
-17
-0.1% -$959 ﹤0.01% 3659
2020
Q1
$834K Hold
14,242
– – ﹤0.01% 3543
2019
Q4
$1.12M Buy
14,242
+8,238
+137% +$852K ﹤0.01% 3611
2019
Q3
$601K Buy
6,004
+4,415
+278% +$452K ﹤0.01% 3775
2019
Q2
$211K Buy
1,589
+239
+18% +$36.9K ﹤0.01% 3969
2019
Q1
$227K Sell
1,350
-61
-4% -$9.1K ﹤0.01% 3900
2018
Q4
$154K Sell
1,411
-1,928
-58% -$386K ﹤0.01% 3937
2018
Q3
$734K Buy
3,339
+540
+19% +$1.3M ﹤0.01% 3785
2018
Q2
$6M Buy
2,799
+818
+41% +$2.07M ﹤0.01% 3143
2018
Q1
$4.92M Sell
1,981
-12
-0.6% -$26.7K ﹤0.01% 3161
2017
Q4
$3.54M Buy
1,993
+937
+89% +$1.36M ﹤0.01% 3256
2017
Q3
$1.22M Buy
1,056
+510
+93% +$459K ﹤0.01% 3540
2017
Q2
$404K Sell
546
-46
-8% -$28.2K ﹤0.01% 3760
2017
Q1
$402K Hold
592
– – ﹤0.01% 3788
2016
Q4
$437K Sell
592
-46
-7% -$49.2K ﹤0.01% 3757
2016
Q3
$700K Sell
638
-5
-0.8% -$4.36K ﹤0.01% 3673
2016
Q2
$495K Hold
643
– – ﹤0.01% 3798
2016
Q1
$451K Buy
643
+3
+0.5% +$2.6K ﹤0.01% 3811
2015
Q4
$628K Hold
640
– – ﹤0.01% 3767
2015
Q3
$681K Buy
640
+67
+12% +$97.9K ﹤0.01% 3752
2015
Q2
$1.18M Buy
573
+9
+2% +$12.8K ﹤0.01% 3617
2015
Q1
$533K Buy
564
+8
+1% +$7.95K ﹤0.01% 3813
2014
Q4
$569K Buy
556
+9
+2% +$8.03K ﹤0.01% 3687
2014
Q3
$565K Buy
547
+40
+8% +$59K ﹤0.01% 3682
2014
Q2
$979K Sell
507
-19
-4% -$37.6K ﹤0.01% 3491
2014
Q1
$1.12M Buy
526
+85
+19% +$212K ﹤0.01% 3416
2013
Q4
$1.02M Sell
441
-219
-33% -$501K ﹤0.01% 3410
2013
Q3
$1.86M Hold
660
– – ﹤0.01% 3163
2013
Q2
$6.1M Buy
+660
New +$5.09M ﹤0.01% 2552

Other funds holding ONCT

Vanguard Group's ONCT Position: Q4 2024 in Review

Vanguard Group sold out of Oncternal Therapeutics (ONCT) in Q4 2024, closing a stake of 139,884 shares — an estimated $185K sold.

Vanguard Group first reported a position in ONCT in Q2 2013 and held it in 46 quarters. The position peaked at $14.7M in Q1 2021. 4 funds tracked by Wall St. Rank hold ONCT as of Q4 2024.

  • Vanguard Group reported no remaining Oncternal Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Vanguard Group sold 139,884 Oncternal Therapeutics shares in Q4 2024, an estimated $185K.
  • Vanguard Group first reported a position in Oncternal Therapeutics in Q2 2013 and held it in 46 quarters.
  • Vanguard Group's Oncternal Therapeutics position peaked at $14.7M in Q1 2021.
  • 4 funds tracked by Wall St. Rank held Oncternal Therapeutics as of Q4 2024.

Based on Vanguard Group's 13F filing for Q4 2024, filed 11 Feb 2025.